comb. nov. Int J Syst Evol Microbiol 34:31-34, 1984
2)Jett BD, et al:Virulence of enterococci. Clin Microbiol Review 7:462-478, 1994
3)Gilmore MS, et al:Enterococci;From commensals to leading causes of drug resistant infection. Massachusetts Eye and Ear Infirmary, Boston, 2014
4)Zervos MJ, et al:Reversal of the in vitro susceptibility of enterococci to trimethoprim-sulfamethoxazole by folinic acid. Antimicrob Agents Chemother 28:446-448, 1985
5)厚生労働省院内感染対策サーベイランス事業(JANIS):検査部門公開情報2020年1月〜12月年報. https://janis.mhlw.go.jp/report/open_report/2020/3/1/ken_Open_Report_202000.pdf(2022年3月閲覧)
. N Engl J Med 319:157-161, 1988
7)Uttley AH, et al:High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Infect 103:173-181, 1989
8)Weiner-Lastinger LM, et al:Antimicrobial-resistant pathogens associated with adult healthcare-associated infections;Summary of data reported to the National Healthcare Safety Network, 2015-2017. Infect Control Hosp Epidemiol 41:1-18, 2020
9)富田治芳,他:バンコマイシン耐性腸球菌.日臨微生物会誌24:180-194, 2014
10)CLSI:M100;Performance Standards for Antimicrobial Susceptibility Testing. 32nd ed. Clinical and Laboratory Standards Institute, Wayne, 2022
infective endocarditis. Clin Infect Dis 56:1261-1268, 2013
12)The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 12.0, 2022. http://www.eucast.org(2022年3月閲覧)